Jennifer is a Sr. Principal Scientist in the Cell Therapy Development organization at Bristol Myers Squibb. In her current role, she heads the Impurity Sciences & Analytics group and oversees impurity strategy and support for several cell therapy programs. Prior to joining BMS, Jennifer worked in the Protein Analytical Chemistry group at Genentech where she contributed to the development of chromatographic, electrophoretic, and LCMS-based methods for antibody characterization. Jennifer received her B.S. in Chemistry from UC Berkeley and her Ph.D. in Biological Chemistry from MIT. Outside of work, Jennifer enjoys being outdoors including indulging in hobbies like hiking and snow sports.